Literature DB >> 16051539

Efficient drug delivery to atherosclerotic lesions and the antiatherosclerotic effect by dexamethasone incorporated into liposomes in atherogenic mice.

Sumio Chono1, Yoshihiko Tauchi, Yoshiharu Deguchi, Kazuhiro Morimoto.   

Abstract

In order to confirm the efficacy of dexamethasone (DXM) incorporated into liposomes (DXM-liposomes) on atherosclerosis, drug delivery to atherosclerotic lesions and the antiatherosclerotic effect by DXM-liposomes were investigated in atherogenic mice. DXM-liposomes were prepared with egg yolk phosphatidylcholine, cholesterol and dicetylphosphate in a lipid molar ratio of 7/2/1 by the hydration method and then adjusted to three different particle sizes to clarify the influence of particle size on the drug delivery to atherosclerotic lesions and the effect on atherosclerosis. The particle sizes of DXM-liposomes were 519 nm (L500), 202 nm (L200) and 68.6 nm (L70), respectively. In both size, DXM concentration and DXM/lipid molar ratio in DXM-liposomes suspension were 1 mg DXM/ml and 0.134 mol DXM/mol total lipids, respectively. Atherogenic mice used as an experimental model develop an atherosclerotic lesion in the aorta and they were prepared by feeding an atherogenic diet for 14 weeks. The aortic pharmacokinetics of DXM-liposomes was examined by intravenous administration to atherogenic mice. The aortic uptake clearance of DXM in atherogenic mice treated with L200 was 2.6--3.2 fold greater than that in animals treated with L500, L70 or free DXM (f-DXM). Furthermore, the effects of DXM-liposomes on atherosclerosis were examined by intravenous administration to atherogenic mice once a week from 8 to 14 weeks. The antiatherosclerotic effects of DXM-liposomes were evaluated by determination of the aortic cholesterol ester (CE) level. The aortic CE level in atherogenic mice treated with L200 (55 microg DXM/kg) was significantly lower than that in animals treated with PBS. The antiatherosclerotic effect of L200 (55 microg DXM/kg) was significantly more potent than that of f-DXM (550 microg DXM/kg). These findings suggest that efficient delivery of DXM to the atherosclerotic lesions by L200 induces an excellent antiatherosclerotic effect at a lower dose. Therefore, L200 may be useful in the development of drug delivery systems for atherosclerotic therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051539     DOI: 10.1080/10611860500159030

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  12 in total

Review 1.  Designing polymers with sugar-based advantages for bioactive delivery applications.

Authors:  Yingyue Zhang; Jennifer W Chan; Alysha Moretti; Kathryn E Uhrich
Journal:  J Control Release       Date:  2015-09-28       Impact factor: 9.776

2.  Lysophosphatidylcholine reduces the organ injury and dysfunction in rodent models of gram-negative and gram-positive shock.

Authors:  Oliver Murch; Marika Collin; Bruno Sepodes; Simon J Foster; Helder Mota-Filipe; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 3.  Detection and treatment of atherosclerosis using nanoparticles.

Authors:  Jia Zhang; Yujiao Zu; Chathurika S Dhanasekara; Jun Li; Dayong Wu; Zhaoyang Fan; Shu Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-05-31

4.  Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone.

Authors:  Jonas H Graversen; Pia Svendsen; Frederik Dagnæs-Hansen; Jakob Dal; Gabriele Anton; Anders Etzerodt; Mikkel D Petersen; Peter A Christensen; Holger J Møller; Søren K Moestrup
Journal:  Mol Ther       Date:  2012-05-29       Impact factor: 11.454

5.  Antioxidant Response Activating nanoParticles (ARAPas) localize to atherosclerotic plaque and locally activate the Nrf2 pathway.

Authors:  Sophie Maiocchi; Ana Cartaya; Sydney Thai; Adam Akerman; Edward Bahnson
Journal:  Biomater Sci       Date:  2022-03-02       Impact factor: 7.590

6.  Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis.

Authors:  Mark E Lobatto; Zahi A Fayad; Stephane Silvera; Esad Vucic; Claudia Calcagno; Venkatesh Mani; Stephen D Dickson; Klaas Nicolay; Manuela Banciu; Raymond M Schiffelers; Josbert M Metselaar; Louis van Bloois; Hai-Shan Wu; John T Fallon; James H Rudd; Valentin Fuster; Edward A Fisher; Gert Storm; Willem J M Mulder
Journal:  Mol Pharm       Date:  2010-11-08       Impact factor: 4.939

7.  Targeted liposomal drug delivery to monocytes and macrophages.

Authors:  Ciara Kelly; Caroline Jefferies; Sally-Ann Cryan
Journal:  J Drug Deliv       Date:  2010-10-26

Review 8.  Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology.

Authors:  Fernando Pena-Ortega
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 9.  Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension.

Authors:  Victor Segura-Ibarra; Suhong Wu; Nida Hassan; Jose A Moran-Guerrero; Mauro Ferrari; Ashrith Guha; Harry Karmouty-Quintana; Elvin Blanco
Journal:  Front Physiol       Date:  2018-07-13       Impact factor: 4.566

10.  Increasing Atherosclerosis in Streptozotocin-Induced Diabetes into Four Groups of Mice.

Authors:  Kiking Ritarwan; Aznan Lelo; Yunita Sari Pane; Nerdy Nerdy
Journal:  Open Access Maced J Med Sci       Date:  2018-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.